Appili Therapeutics Announces Results of Special Meeting of Shareholders

Core Viewpoint - Appili Therapeutics Inc. has received overwhelming shareholder approval for a plan of arrangement to be acquired by Aditxt Inc. through its subsidiary Adivir, Inc. This transaction is aimed at advancing Appili's pipeline of anti-infective therapies and enhancing its mission to combat severe infectious diseases [1][2]. Shareholder Meeting Results - A total of 35,770,287 Appili Shares were voted, representing approximately 29.50% of the outstanding shares [2] - The transaction was approved by 99.79% of the votes cast by shareholders and 99.65% when excluding certain votes [2] Strategic Implications - The alignment with Aditxt is expected to enhance Appili's access to capital and create new opportunities in the infectious diseases sector [3] - Appili aims to prepare its drug ATI1701 for IND submission and implement FDA strategies for ATI-1801, while also enhancing commercialization for LIKMEZ™ [3] Transaction Conditions - The transaction is subject to customary closing conditions and Aditxt must raise at least US$20 million in financing [3] - The expected closing date for the transaction is in Q4 2024 [3] Company Profiles - Appili Therapeutics focuses on developing novel therapies for life-threatening infections, with a portfolio that includes an FDA-approved metronidazole suspension and a vaccine candidate [5] - Aditxt operates as an innovation platform aimed at accelerating health innovations, with a collaborative ecosystem involving research institutions and industry partners [6]